每经AI快讯，有投资者在投资者互动平台提问：公司旗下爱森泽生物的虾青素，是天然藻源还是化学 合成？技术路线是什么？当前虾青素原料市场涨价明显，公司是否有提价计划、产能规划及成本控制措 施？ 沃森生物（300142.SZ）2月26日在投资者互动平台表示，目前为天然藻源。关于相关产品和项目的后续 情况请持续关注公司披露的信息。 （文章来源：每日经济新闻） ...

| 序号 | 代码 | 名称 | 估算权可 | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | --- | | 1 | 2269 | 药明生物 | 12.83% | 1.47% | 5.49亿 | | 2 | 6160 | 百济神州 | 10.76% | -2.20% | 6.38亿 | | 3 | 1801 | 信达生物 | 9.33% | -0.34% | 6.44Z | | 4 | 1093 | 石药集团 | 7.45% | -0.99% | 6.04Z | | 5 | 9926 | 康方生物 | 7.05% | 0.58% | 3.82亿 | | 6 | 1177 | 中国生物制药 | 6.06% | -0.16% | 2.447. | | 7 | 2359 | 药明康德 | 5.23% | -0.82% | 2.95亿 | | 8 | 3692 | 翰森制药 | 4.81% | -0.23% | 1.53亿 | | ਰੇ | 1530 | 三生制药 | 3.99% | 0.63% | 2.76亿 | | 10 | 2228 | 晶泰控股 | 3.37% | - ...

Summary of Key Points Core Viewpoint The article discusses the recent developments in China's mother fund industry, highlighting the total management scale of 1161.5 billion yuan, with investments spanning various sectors such as artificial intelligence, new production capacity, and integrated circuits. The article provides insights into fund management recruitment, fund establishment, and LP contributions across different provinces. Fund Management Recruitment - Hebei Province is seeking GP for its Science and Technology Investment Guidance Fund to support strategic and future industries [7] - Sichuan Province is recruiting GP for the Cultural Tourism New Quality Productivity Industry Fund [15] - Chongqing is looking for GP for the Rongchang Mother Fund [17] - Gansu Province is inviting GP for the Jiuquan Science and Technology and Industry Development Fund [20] - Other provinces such as Guangdong, Yunnan, Jiangsu, and Hubei are also actively recruiting GPs for various funds [5][6][43] Fund Establishment - The Jiangsu Super Mother Fund has signed agreements totaling 691 billion yuan, focusing on strategic emerging industries [33][36] - The Yunnan Advanced Manufacturing Equity Investment Mother Fund aims to enhance industrial competitiveness and promote high-quality development [28] - The Shanghai Integrated Circuit Industry Investment Fund has increased its capital to 60.3 billion yuan, marking a significant growth of approximately 1038% [55] LP Contributions - Watson Bio has initiated the establishment of the Yunnan Chuangwo Biological Industry Investment Fund with a target size of 1 billion yuan, contributing 450 million yuan [44] - Jinzhitech plans to invest 240 million yuan to establish an industrial fund in collaboration with local partners [46] - The establishment of the Hohhot Zhongjin Qixin Equity Investment Fund has been announced, with a total investment of 10 billion yuan [51] Other Developments - The establishment of the Ezhou Intelligent Development Equity Investment Fund with a total scale of 30 billion yuan aims to support the AI industry [43] - The Jiangsu Province has successfully registered two industry mother funds with a total scale of 6.5 billion yuan, focusing on smart manufacturing and industrial development [41]

Core Viewpoint - Watson Bio has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund, with a target size of 1 billion yuan, where the company will contribute 450 million yuan, accounting for 45% of the fund [1] Group 1: Investment Fund Details - The fund is initiated in collaboration with Guotou Chuangyi Industrial Fund Management Co., Ltd. and other parties [1] - The core investment focus of the fund is on synthetic biology, biomanufacturing, and biotechnology-related industries [1] Group 2: Strategic Implications - The establishment of the fund allows the company to closely engage with high-quality targets in the relevant fields [1] - This initiative is expected to provide rare opportunities for direct collaboration with target enterprises, laying the foundation for future industrial synergy and strategic mergers and acquisitions [1]

Core Viewpoint - Watson Bio is advancing its 20-valent pneumococcal polysaccharide conjugate vaccine, currently in the preparation stage for Phase I clinical trials, building on its existing 13-valent vaccine [2] Group 1: Vaccine Development - The 20-valent pneumococcal conjugate vaccine includes seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) beyond those in the 13-valent vaccine, aimed at preventing infections caused by a total of 20 serotypes [2] - The efficacy of the 20-valent pneumococcal conjugate vaccine will be determined based on the final results of efficacy clinical trials [2] Group 2: Other Vaccine Projects - The company is also preparing for Phase I clinical trials for its respiratory syncytial virus mRNA vaccine and its freeze-dried varicella-zoster virus mRNA vaccine, expected to receive approval for trials in October and December 2025, respectively [2]

Group 1 - The core viewpoint of the article is that Watson Bio (300142) is currently in the Phase III clinical research stage for its nine-valent HPV vaccine [1] - The company stated that updates regarding the vaccine's development progress should be based on announcements disclosed by the company [1]

Policy Developments - The National Health Commission and 10 other departments jointly issued the "National Basic Drug Directory Management Measures," which revises six key areas, including legal policy basis, directory structure optimization, management mechanism improvement, emphasis on clinical value, dynamic adjustment mechanism, and monitoring and evaluation enhancement [1][2]. Drug and Device Approvals - Hengrui Medicine announced that its injection of Rukang Qutuzumab has been included in the list of breakthrough therapy varieties, marking the 10th indication for this drug, aimed at treating locally advanced or metastatic non-small cell lung cancer patients with HER2 mutations [3]. - Shanghai Pharmaceuticals received approval for the listing application of the raw material drug Tamsulosin Hydrochloride, which is used for treating benign prostatic hyperplasia, with an investment of approximately RMB 1.5 million in its development [4]. Financial Reports - WuXi Biologics expects a 46.3% year-on-year increase in net profit for the full year 2025, projecting revenues of approximately RMB 21.79 billion and an adjusted net profit of about RMB 6.59 billion [5]. - Eucare Pharmaceuticals reported a 48.21% decline in net profit for 2025, with revenues of RMB 334 million, reflecting a 7.73% increase [6]. Capital Markets - Watson Bio plans to invest RMB 450 million to establish a biological industry investment fund with a target size of RMB 1 billion, focusing on synthetic biology and related sectors [7]. - Hite Bio intends to acquire a 23.08% stake in Beijing Shadong for RMB 62.02 million, increasing its ownership to 98.84% [8]. - Duorui Pharmaceuticals announced a partial tender offer to acquire 24.30% of its shares at a price of RMB 32.07 per share [9]. Industry Events - China's first C909 "airplane hospital" successfully completed its first in-flight surgery in Laos, providing medical services to over 600 patients since its launch [10]. - Researchers revealed the key mechanism of the "weight loss miracle drug" Semaglutide, showing its significant cartilage protection effects independent of weight loss, providing new drug development targets for metabolic osteoarthritis [11]. Public Sentiment Alerts - Shuyou Shen announced that its major shareholder, Xiangtang Group, has cumulatively reduced its holdings by 4.78 million shares, accounting for 1% of the total share capital [12].

Group 1 - The National Health Commission and 11 other departments issued the "National Essential Drug Directory Management Measures," revising six key areas to enhance the essential drug system in China [1] - The revised measures include optimizing the directory structure, categorizing drugs into chemical drugs, biological products, and traditional Chinese medicine based on clinical pharmacology and functionality [1] - The management mechanism for the directory has been improved, emphasizing the clinical value of drugs and considering factors such as disease spectrum changes and drug supply assurance [1] Group 2 - Reborna Biotech and Madrigal Pharmaceuticals entered a global exclusive licensing agreement worth $4.4 billion to develop innovative siRNA therapies for metabolic dysfunction-related fatty liver disease (MASH) [2] - Reborna will receive a $60 million upfront payment and is eligible for additional payments upon achieving clinical development and regulatory milestones, along with royalties based on global net sales [2] - The agreement highlights the international value of domestic innovative drugs and the urgent demand for effective therapies in the MASH field, indicating significant market potential [2] Group 3 - Watson Bio announced plans to invest 450 million yuan to establish a biological industry investment fund, targeting a total fund size of 1 billion yuan [3] - The fund will primarily invest in the synthetic biology manufacturing sector, including areas such as synthetic biology, health, bio-agriculture, bio-energy, and bio-materials [3] - This initiative is expected to help Watson Bio capture industry benefits and lay the groundwork for future strategic mergers and acquisitions [3] Group 4 - Hengrui Medicine's subsidiary, Suzhou MSD Biopharmaceutical Co., has had its drug SHR-A1811 included in the list of breakthrough therapies by the National Medical Products Administration [4] - SHR-A1811 is intended for first-line treatment of locally advanced or metastatic non-small cell lung cancer patients with HER2 (ERBB2) activating mutations [4] - The inclusion of SHR-A1811 reflects Hengrui's research achievements in the ADC field, although it will face competition from several already approved similar products [4]

Core Viewpoint - Watson Bio (300142.SZ) announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund, with a target size of 1 billion yuan, to focus on synthetic biology, biomanufacturing, and biotechnology sectors [1] Group 1: Investment Details - The board of directors approved the partnership agreement with Guotou Chuangyi Industrial Fund Management Co., Ltd., Yuxi State-owned Capital Operation Co., Ltd., and Central Enterprise Rural Industry Investment Fund Co., Ltd. [1] - Watson Bio will contribute 450 million yuan as a limited partner in the fund [1] Group 2: Strategic Implications - The investment aligns with national bio-economy development plans, creating multiple opportunities for the company to capture industry benefits [1] - The collaboration with Guotou Chuangyi will enable the company to rapidly expand business channels and access high-quality market opportunities and partners [1] - Direct participation in fund operations will allow the company to engage closely with quality targets in the relevant fields, facilitating strategic mergers and acquisitions [1]

Core Viewpoint - Watson Bio (300142.SZ) has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners, aiming for a target size of 1 billion yuan, with the company contributing 450 million yuan as a limited partner [1] Group 1: Investment Fund Details - The fund's target size is set at 1 billion yuan [1] - Watson Bio will invest 450 million yuan of its own funds as a limited partner [1] - The fund will focus on various investment areas including synthetic biology, life and health, biological agriculture, bioenergy, biomaterials, technology platform enterprises, and high-throughput equipment [1] Group 2: Investment Areas - Investment areas include synthetic biology such as enzyme preparations, amino acids, and probiotics [1] - Life and health investments will cover plant extracts, recombinant collagen, sweeteners, and protein drugs [1] - Biological agriculture will focus on feed protein, micro-ecological preparations, animal vaccines, and biological nitrogen fixation [1] - Bioenergy investments will include bioethanol and biodiesel [1] - Biomaterials will focus on PLA, PHA, and PDO [1] - The fund will also target technology platform enterprises like strain development and AI protein design [1] - High-throughput equipment investments will include microfluidic devices and gene sequencing equipment [1]